🇺🇸 HLX10 in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 4
Most-reported reactions
- Eating Disorder — 1 report (25%)
- Lymphocyte Count Decreased — 1 report (25%)
- Neutrophil Count Decreased — 1 report (25%)
- White Blood Cell Count Decreased — 1 report (25%)
HLX10 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is HLX10 approved in United States?
HLX10 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for HLX10 in United States?
Shanghai Henlius Biotech is the originator. The local marketing authorisation holder may differ — check the official source linked above.